Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL241 Target Snapshot

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,260Compounds
244Assays
4Approved Drugs
1,107.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A shows approved-linked disease relevance led by Airway obstruction. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q14432. Start with Airway obstruction, then reuse UniProt Q14432 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Airway obstruction, then reuse UniProt Q14432 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
Airway obstruction

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A shows approved-linked disease relevance led by Airway obstruction. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with Airway obstruction because it currently carries approved-linked support. Linked drugs include DYPHYLLINE, IBUDILAST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A as ChEMBL target CHEMBL241, mapped to UniProt Q14432. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL241
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q14432
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A is the right protein anchor across sources, using UniProt Q14432 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Airway obstruction is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamecGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ14432
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
UniProt AccessionQ14432
Component TypeProtein
Sequence Length1141 aa

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A, mapped to UniProt Q14432. Sequence length is 1141 aa.

Mapped IDQ14432
Review namecGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A shows approved-linked disease relevance led by Airway obstruction. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Airway obstruction
2 linked drugs · 2 direct · 2 efficacy
Linked drugDYPHYLLINE
Linked drugIBUDILAST
Approved-linked Approved
heart failure
2 linked drugs · 2 direct · 2 efficacy
Linked drugCILOSTAZOL
Linked drugMILRINONE LACTATE
Approved-linked Approved
Recurrent thrombophlebitis
1 linked drug · 1 direct · 1 efficacy
Linked drugCILOSTAZOL
Approved-linked Approved
Ventricular arrhythmia
1 linked drug · 1 direct · 1 efficacy
Linked drugMILRINONE LACTATE
Late clinical Phase III
atherosclerosis
1 linked drug · 1 direct · 1 efficacy
Linked drugCILOSTAZOL
Late clinical Phase III
cardiovascular disease
1 linked drug · 1 direct · 1 efficacy
Linked drugCILOSTAZOL
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Airway obstruction because it currently carries approved-linked support. Linked drugs include DYPHYLLINE, IBUDILAST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseAirway obstruction
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
2
Phase III
2
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC501,016.0
KI88.0
EC502.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL338860 9.96 IC50 0.11 Preclinical
CHEMBL339210 9.96 IC50 0.11 Preclinical
CHEMBL2337969 9.57 IC50 0.27 Preclinical
CHEMBL131355 9.48 IC50 0.33 Preclinical
CHEMBL131111 9.41 IC50 0.39 Preclinical
CHEMBL338381 9.08 IC50 0.83 Preclinical
CHEMBL128621 9.03 IC50 0.94 Preclinical
CHEMBL128391 8.92 IC50 1.2 Preclinical
CHEMBL2337953 8.92 IC50 1.2 Preclinical
CHEMBL128456 8.89 IC50 1.3 Preclinical
Distribution

pChEMBL Value Distribution

81
5.0
71
5.5
64
6.0
155
6.5
161
7.0
57
7.5
32
8.0
15
8.5
4
9.0
3
9.5
pChEMBL
Approved Drugs

Approved Drugs

CILOSTAZOL
CHEMBL799
Approved 1999
Properties Compare Identifier
MILRINONE
CHEMBL189
Approved 1987
Properties Compare Identifier
Assay Landscape

Assay Landscape

244
Total Assays
725
Tested Compounds
3
Assay Types
Binding — 229 assays, 725 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 190 296 5.8
cell-based format 25 110 6.2
assay format 14 319 7.2
ADME — 11 assays, 26 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 7 17 5.2
cell-based format 4 9 5.8
Functional — 4 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 0 —
cell-based format 1 1 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine